Drug-resistant tuberculosis
Conditions
Interventions
Experimental group:Treatment of rifampicin-resistant pulmonary tuberculosis with a regimen containing contezolamide
Linezolid control group:A regimen containing linezolid for the treatment of rifampicin-resistant tuberculosis
Sponsors
Beijing Chest Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1: Age of subjects: 18 years old =65 years old, male or female 2: Subject weight: 40kg= 90kg 3: Rifampicin resistance (RR-TB) was diagnosed by molecular biology 4: The sputum smear was positive for acid-fast bacilli (AFB at least 1+) 5: HIV test negative 6: For non-lactating and pregnant women, consent to continue using contraception throughout the treatment 7: Fully understand the purpose and requirements of this experiment, voluntarily sign the written informed consent and agree to abide by the requirements and restrictions set forth in the informed consent and Agreement
Exclusion criteria
Exclusion criteria: 1: Drug sensitivity results show that there is a history of resistance to the drug in the regimen or allergy to any of the ingredients in the regimen, or are taking any drug that is contraindicated with the drug in the regimen 2: Severe renal and liver insufficiency 3: Unable to attend or comply with treatment and follow-up 4: QTcF interval > 500 ms 5: Have a history of or are suffering from cardiovascular diseases such as heart failure, hypertension (poorly controlled blood pressure), arrhythmia or post-myocardial infarction status 6: Pregnant or lactating women 7: HIV positive or AIDS patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy index; | — |
Countries
China
Contacts
Public ContactWang Jun/ Chu Naihui
Beijing Chest Hospital affiliated to Capital Medical University
Outcome results
None listed